Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : XOMA
Deal Size : $490.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, XOMA has acquired all rights to ebopiprant held by ObsEva, including the Organon/ObsEva license agreement and the IP associated with the asset.
Brand Name : OBE022
Molecule Type : Small molecule
Upfront Cash : $15.0 million
November 22, 2022
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : XOMA
Deal Size : $490.0 million
Deal Type : Acquisition
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Organon
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022)
Details : Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.
Brand Name : OBE022
Molecule Type : Small molecule
Upfront Cash : $500.0 million
July 27, 2021
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Organon
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ebopiprant, when administered with atosiban infusion to women with preterm labor, reduced delivery in singleton pregnancies at 48 hours after the start of dosing by over 50% compared to atosiban alone.
Brand Name : OBE022
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2021
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the PROLONG study, ebopiprant reduced delivery in singleton pregnancies at 48 hours after the start of dosing by 55% compared to atosiban alone. Overall, 12.5% of women receiving ebopiprant delivered within 48 hours of starting treatment compared to p...
Brand Name : OBE022
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2020
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?